Patents by Inventor Tiziano Bandiera

Tiziano Bandiera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20230212157
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
    Type: Application
    Filed: February 1, 2023
    Publication date: July 6, 2023
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • Pyrazole derivatives for the treatment of cystic fibrosis
    Patent number: 11597723
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: March 7, 2023
    Assignees: Fondazione Istituto Italiano Di Technologia, Istituto Giannina Gasiini, FondaZione Per La Ricerca Sulla Fibrosi Cristica—Onlus
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20220089584
    Abstract: The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular to modulate CFTR protein or ABC protein activities.
    Type: Application
    Filed: January 16, 2020
    Publication date: March 24, 2022
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Giorgia Zaetta, Frederico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20210292324
    Abstract: The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular to modulate CFTR protein or ABC protein activities.
    Type: Application
    Filed: July 12, 2019
    Publication date: September 23, 2021
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Francesca Giacomina, Simone Giovani, Federico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • Compounds and compositions for the treatment of cystic fibrosis
    Patent number: 10968225
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: April 6, 2021
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Francesco Berti, Alejandra Rodriguez Gimeno, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
    Patent number: 10865194
    Abstract: Pharmaceutical compounds are disclosed having a bicyclic-sulphonamide structure of Formula 1: wherein R1 represents an unsubstituted or a substituted heteroaryl ring; R2, R3, R4, and R5 are independently selected from hydrogen, alkyl, hydroxyalkyl, and alkyl-O-alkyl, provided that either R2 and R3, or R4 and R5 are linked or taken together to form a bridge between the carbon atoms to which R2 and R3, or R4 and R5 respectively are directly linked, whereby the N-containing ring in Formula 1 is an azabicyclo moiety. The compounds and compositions including the compounds may be used in therapy as brain-cell-death protectants, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: December 15, 2020
    Assignee: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
    Inventors: Fabio Bertozzi, Tiziano Bandiera, Silvia Pontis, Angelo Reggiani, Francesca Giacomina, Paolo Di Fruscia
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20200369663
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
    Type: Application
    Filed: August 14, 2020
    Publication date: November 26, 2020
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Francesco Berti, Alejandra Rodriguez Gimeno, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • Heterocyclic derivatives for the treatment of cystic fibrosis
    Patent number: 10745407
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: August 18, 2020
    Assignee: Fondazione Istituto Italiano Di Tecnologia
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Francesco Berti, Alejandra Rodriguez Gimeno, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20200131157
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof. It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
    Type: Application
    Filed: March 14, 2018
    Publication date: April 30, 2020
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20200002348
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
    Type: Application
    Filed: March 14, 2018
    Publication date: January 2, 2020
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Francesco Berti, Alejandra Rodriguez Gimeno, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments
    Patent number: 10435355
    Abstract: Described herein, inter alia, are compositions and methods useful for inhibiting fatty acid amide hydrolase.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: October 8, 2019
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Tecnologia
    Inventors: Daniele Piomelli, Tiziano Bandiera, Rita Scarpelli
  • Modulation of N-acylethanolamine-hydrolysing acid amidase (NAAA) for disease treatment
    Patent number: 10364242
    Abstract: Pharmaceutical compositions make up a compound acting as inhibitor of N-acylethanolamine-hydrolyzing acid amidase (NAAA), may be used for the therapeutical treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamines, particularly palmitoylethanolamide (PEA). The compound is used in methods of inhibiting NAAA and methods of therapeutical treatment and prevention of pain and inflammation.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: July 30, 2019
    Assignee: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA
    Inventors: Fabio Bertozzi, Tiziano Bandiera
  • THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20190135778
    Abstract: Pharmaceutical compounds have a bicyclic-sulphonamide structure and pharmaceutical compositions including the compounds may be used in therapy as brain-cell-death protectants and may be used, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).
    Type: Application
    Filed: November 3, 2017
    Publication date: May 9, 2019
    Inventors: Fabio BERTOZZI, Tiziano BANDIERA, Silvia PONTIS, Angelo REGGIANI, Francesca GIACOMINA, Paolo DI FRUSCIA
  • MODULATION OF N-ACYLETHANOLAMINE-HYDROLYSING ACID AMIDASE (NAAA) FOR DISEASE TREATMENT
    Publication number: 20190135802
    Abstract: Pharmaceutical compositions make up a compound acting as inhibitor of N-acylethanolamine-hydrolysing acid amidase (NAAA), may be used for the therapeutical treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamines, particularly palmitoylethanolamide (PEA). The compound is used in methods of inhibiting NAAA and methods of therapeutical treatment and prevention of pain and inflammation.
    Type: Application
    Filed: November 3, 2017
    Publication date: May 9, 2019
    Inventors: Fabio BERTOZZI, Tiziano BANDIERA
  • INHIBITORS OF FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME WITH IMPROVED ORAL BIOAVAILABILITY AND THEIR USE AS MEDICAMENTS
    Publication number: 20180194722
    Abstract: Described herein, inter alia, are compositions and methods useful for inhibiting fatty acid amide hydrolase.
    Type: Application
    Filed: October 13, 2017
    Publication date: July 12, 2018
    Inventors: Daniele PIOMELLI, Tiziano Bandiera, Rita Scarpelli
  • Diarylalkylamine REV-ERB antagonists and their use as medicaments
    Patent number: 9949968
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and proapoptotic agents for cancer therapy.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: April 24, 2018
    Assignee: Fondazione Istituto Italiano Di Tecnologia
    Inventors: Benedetto Grimaldi, Esther Torrente, Rita Scarpelli, Giovanni Bottegoni, Tiziano Bandiera, Marina Veronesi
  • Amide derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors
    Patent number: 9908848
    Abstract: Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: March 6, 2018
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Tecnologia, Universita Degli Studi di Urbino “Carlo Bo”, Universita Degli Studi di Parma
    Inventors: Daniele Piomelli, Marco Mor, Giorgio Tarzia, Fabio Bertozzi, Andrea Nuzzi, Annalisa Fiasella, Tiziano Bandiera, Angelo Mario Reggiani
  • Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR)
    Patent number: 9828352
    Abstract: The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar?, R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: November 28, 2017
    Assignees: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Giovanni Bottegoni, Alessio De Simone, Gian Filippo Ruda, Andrea Cavalli, Tiziano Bandiera, Daniele Piomelli
  • Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors
    Patent number: 9828338
    Abstract: Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: November 28, 2017
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Technologia, Universita Degli Studi di Urbino “Carlo Bo”, Universita Degli Studi di Parma
    Inventors: Daniele Piomelli, Tiziano Bandiera, Fabio Bertozzi, Andrea Nuzzi, Annalisa Fiasella, Stefano Ponzano, Chiara Pagliuca, Angelo Mario Reggiani, Marco Mor, Giorgio Tarzia
  • Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments
    Patent number: 9822068
    Abstract: Described herein, inter alia, are compositions and methods useful for inhibiting fatty acid amide hydrolase.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: November 21, 2017
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Technologia
    Inventors: Daniele Piomelli, Tiziano Bandiera, Rita Scarpelli